(Q51752588)

11 April 2018

editorial

0 references

review article

1 reference

title

Multiple protective pathways against reperfusion injury: a SAFE path without Aktion? (English)

1 reference

11 April 2018

1 reference

Sandrine Lecour

1

1 reference

11 April 2018

publication date

20 January 2009

1 reference

11 April 2018

Journal of Molecular and Cellular Cardiology

published in

1 reference

11 April 2018

volume

46

1 reference

11 April 2018

issue

5

1 reference

11 April 2018

page(s)

607-609

1 reference

11 April 2018

Myocardial reperfusion injury.

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2009.01.003

Reperfusion injury in humans: a review of clinical trials on reperfusion injury inhibitory strategies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2009.01.003

Inhibition of myocardial injury by ischemic postconditioning during reperfusion: comparison with ischemic preconditioning

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2009.01.003

Long-term benefit of postconditioning

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2009.01.003

Postconditioning the human heart

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2009.01.003

Signaling pathways involved in the cardioprotective effects of cannabinoids

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2009.01.003

Endothelial CB1-receptors limit infarct size through NO formation in rat isolated hearts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2009.01.003

CB(2) cannabinoid receptor activation is cardioprotective in a mouse model of ischemia/reperfusion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2009.01.003

Endocannabinoids and the control of energy balance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2009.01.003

Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2009.01.003

SERENADE: the Study Evaluating Rimonabant Efficacy in Drug-naive Diabetic Patients: effects of monotherapy with rimonabant, the first selective CB1 receptor antagonist, on glycemic control, body weight, and lipid profile in drug-naive type 2 diabete

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2009.01.003

CB1 receptor blockade and its impact on cardiometabolic risk factors: overview of the RIO programme with rimonabant

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2009.01.003

Cardioprotection: nitric oxide, protein kinases, and mitochondria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2009.01.003

Persistent beneficial effect of postconditioning against infarct size: role of mitochondrial K(ATP) channels during reperfusion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2009.01.003

The mitochondrial permeability transition pore: its fundamental role in mediating cell death during ischaemia and reperfusion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2009.01.003

Effect of cyclosporine on reperfusion injury in acute myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2009.01.003

New directions for protecting the heart against ischaemia-reperfusion injury: targeting the Reperfusion Injury Salvage Kinase (RISK)-pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2009.01.003

Pharmacological preconditioning with tumor necrosis factor-alpha activates signal transducer and activator of transcription-3 at reperfusion without involving classic prosurvival kinases (Akt and extracellular signal-regulated kinase).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2009.01.003

Dual activation of STAT-3 and Akt is required during the trigger phase of ischaemic preconditioning

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2009.01.003

Ischemic postconditioning in pigs: no causal role for RISK activation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2009.01.003

The myocardial JAK/STAT pathway: from protection to failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2009.01.003

Cardioprotection by ischemic postconditioning is lost in aged and STAT3-deficient mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2009.01.003

Signal transducer and activator of transcription 3 is involved in the cardioprotective signalling pathway activated by insulin therapy at reperfusion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2009.01.003

The JAK/STAT pathway is essential for opioid-induced cardioprotection: JAK2 as a mediator of STAT3, Akt, and GSK-3 beta

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2009.01.003

Diabetes abolishes morphine-induced cardioprotection via multiple pathways upstream of glycogen synthase kinase-3beta

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2009.01.003

TNFalpha is required to confer protection in an in vivo model of classical ischaemic preconditioning

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2009.01.003

Beneficial effects of intracoronary adenosine as an adjunct to primary angioplasty in acute myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2009.01.003

Intravenous nicorandil can preserve microvascular integrity and myocardial viability in patients with reperfused anterior wall myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2009.01.003

Intravenous diltiazem in acute myocardial infarction. Diltiazem as adjunctive therapy to activase (DATA) trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2009.01.003

'Postconditioning' the human heart: multiple balloon inflations during primary angioplasty may confer cardioprotection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2009.01.003

10.1016/J.YJMCC.2009.01.003

7 January 2021

Identifiers

DOI

1 reference

11 April 2018

PubMed ID

19318238

1 reference

11 April 2018